You have no items in your cart.
Oral NNI-351 Awarded Orphan Drug Status by FDA
Fragile X News Today
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NeuroNascent’s NNI-351 for the treatment of fragile X syndrome. NNI-351, given orally, is able to penetrate the ... Read more